

INFORMATION DISCLOSURE CITATION

Atty. Docket No.: 03804.1129-00000	
Applicant: Jean-Francois DEDIEU et al.	Serial No.: Unassigned
Filing Date: August 31, 2000	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date	Name	Class	Sub Class	Filing Date (if appropriate)
B	1	4,939,088	07/1990	Young et al.	435	320.1	
J	2	5,194,601	03/1993	Sugden et al.	435	320.1	
	3	5,672,344	09/30/97	Kelley et al.	424	172.1	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
B	4	WO 92/05262	4/1992	WIPO			
J	5	WO 93/19191	3/1993	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

B	6	Clayman et al., "Adeno p53 Gene Transfer in a Phase I/II Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma," Soc. for Biol. Therapy, Ann. Meeting, Abstract (1996)
J	7	Clayman et al., "Adenovirus Mediated p53 Gene Transfer in a Phase I Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma," ASCO Annual Meeting, Abstract (1997)
	8	Clayman et al., "Adenovirus Mediated p53 Gene Transfer in Patient with Advanced Recurrent Head and Neck Squamous Carcinoma," AACR Annual Meeting, Abstract
J	9	Clayman et al., "Gene Therapy for Head and Neck Cancer: Comparing the Tumor Suppressor Gene p53 and a Cell Cycle Regulator WAF1/CIP1 (p21)," Arch. Otolaryngol. Head Neck Surgery, Vol. 122, pp. 489-493 (1996)

Examiner: <i>Dalme</i>	Date Considered: <i>5/17/02</i>
* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-1449	
Patent and Trademark Office - U.S. Department of Commerce	

	10	Coghlan , "New Scientist," Vol. 149, pp. 14-15 (1995)
<i>Dr</i>	11	Crystal , "Transfer of genes to humans: early lessons and obstacles to success," Science Vol. 270, pp. 404-409 (1995)
	12	Dong et al. , "Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus," Human Gene Therapy Vol. 7, pp. 319-331 (1996)
	13	Karlsson , "Treatment of genetic defects in hematopoietic cell function by gene transfer," Blood, Vol. 78, No. 10, pp. 2481-2492 (1991)
	14	Kozarsky et al. , "Gene therapy: adenovirus vectors," Current Opinion on Genetics and Development, Vol. 3, pp. 499-503 (1996)
	15	Marshall , "Gene therapy's growing pains," Science, Vol. 269, pp. 1050-1055 (1995)
	16	Marshall , "Less hype, more biology needed for gene therapy," Science, Vol. 270, p. 1751 (1995)
	17	Marx , "Cell death studies yield cancer clues," Science, Vol. 259, pp. 760-761 (1996)
	18	Mastrangeli et al. , "Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer," The Journal of Clinical Investigation, Vol. 91, pp. 225-234 (1993)
	19	Morsy et al. , "Progress toward human gene therapy," JAMA, Vol. 270, No. 19, pp. 2338-2345 (1993)
	20	Orkin & Moltulsky , NIH Report on Gene Therapy, (Dec. 7, 1995)
	21	Perricaudet et al. , Ann. Oncol., Vol. 3, Suppl. 5, p. 135 (1992)
	22	Roth et al. , "Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer," Nature Medicine, Vol. 2, pp. 985-991 (1996)
	23	Sugden et al. , "A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection," Journal of Virology, pp. 2644-2649 (1989)
	24	Swisher et al. , "Persistant Transgene Expression Following Repeated Injections of a Recombinant Adenovirus Containing the p53 Wild-Type Gene in Patients with Non-Small Cell Lung Cancer," AACR Annual Meeting, Abstract
	25	Swisher et al. , "Adenoviral Mediated p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)," ASCO Annual Meeting, Abstract (1997)
<i>Dr</i>	26	Zimber-Strobl et al. , "Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene," Journal of Virology pp. 415-423 (1991)

Examiner:	<i>Dah</i>	Date Considered:	<i>5/17/02</i>
* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO-1449		Patent and Trademark Office - U.S. Department of Commerce	